TY - JOUR
T1 - Combination strategies to maximize the benefits of cancer immunotherapy
AU - Zhu, Shaoming
AU - Zhang, Tian
AU - Zheng, Lei
AU - Liu, Hongtao
AU - Song, Wenru
AU - Liu, Delong
AU - Li, Zihai
AU - Pan, Chong xian
N1 - Funding Information:
TZ: Research funding (to Duke) from Pfizer, Janssen, Acerta, Abbvie, Novartis, Merrimack, OmniSeq, PGDx, Merck, Mirati, Astellas and Regeneron; consulting/speaking with Genomic Health and Sanofi Aventis; and consulting/advisory board with AstraZeneca, Bayer, Pfizer, Foundation Medicine, Janssen, Amgen, BMS, Calithera, Dendreon and MJH Associates; Stock ownership/employment (spouse) from Capio Biosciences, Archimmune Therapeutics and Nanorobotics. LZ: grant support from Bristol-Meyer Squibb, Merck, AstraZeneca, iTeos, Amgen, NovaRock, Inxmed and Halozyme; paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, Datarevive, QED, Xilio, Natera, Novagenesis, Snow Lake Captials and Mingruizhiyao; and shareholder at Alphamab and Mingruzhiyao. HL: research support from Karyopharm and Bristol Myers Squibb, served at advisory board meetings of Agios and a consultant for Beigene, NGM Biopharm. WS: an employee of Kira Pharmaceuticals. DL attended advisory board meetings of AstraZeneca, Beigene, Rigel; serves on the Speaker bureaus of AstraZeneca, Beigene, Incyte, Janssen, Pharmacyclics and Rigel; and has research fundings from Acerta, Celgene, Denovo and Pfizer. ZL: Scientific advisory board member for Heat Biologics, Alphamab (chair), Hengenix and Ioknisys. CXP is a co-founder and shareholder of LP Therapeutics.
Funding Information:
The authors are indebted to all organizing committee members of 2020 China Cancer Immunotherapy Workshop, including those from CAHON (Ke Liu), China NMPA (Feng Zhu, Chenyan Gao, Zhimin Yang) and Tsinghua University School of Medicine (Chen Dong, Xin Lin), as well as all the invited speakers for their contributions to the success of the meeting. The authors apologize to colleagues whose work could not be fully detailed due to space limitations.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will discuss the relationship between cancer immune response and mechanisms of resistance to immunotherapy. It will also provide a comprehensive review on the latest clinical status of combination therapies (e.g., immunotherapy with chemotherapy, radiation therapy and targeted therapy), and discuss combination therapies approved by the US Food and Drug Administration. It will provide an overview of therapies targeting cytokines and other soluble immunoregulatory factors, ACT, virotherapy, innate immune modifiers and cancer vaccines, as well as combination therapies that exploit alternative immune targets and other therapeutic modalities. Finally, this review will include the stimulating insights from the 2020 China Immuno-Oncology Workshop co-organized by the Chinese American Hematologist and Oncologist Network (CAHON), the China National Medical Product Administration (NMPA) and Tsinghua University School of Medicine.
AB - Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will discuss the relationship between cancer immune response and mechanisms of resistance to immunotherapy. It will also provide a comprehensive review on the latest clinical status of combination therapies (e.g., immunotherapy with chemotherapy, radiation therapy and targeted therapy), and discuss combination therapies approved by the US Food and Drug Administration. It will provide an overview of therapies targeting cytokines and other soluble immunoregulatory factors, ACT, virotherapy, innate immune modifiers and cancer vaccines, as well as combination therapies that exploit alternative immune targets and other therapeutic modalities. Finally, this review will include the stimulating insights from the 2020 China Immuno-Oncology Workshop co-organized by the Chinese American Hematologist and Oncologist Network (CAHON), the China National Medical Product Administration (NMPA) and Tsinghua University School of Medicine.
KW - CAR-T
KW - Cancer vaccine
KW - Cytokine
KW - Immune checkpoint inhibitor
KW - Immunotherapy
KW - Oncolytic virus
UR - http://www.scopus.com/inward/record.url?scp=85115768578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115768578&partnerID=8YFLogxK
U2 - 10.1186/s13045-021-01164-5
DO - 10.1186/s13045-021-01164-5
M3 - Review article
C2 - 34579759
AN - SCOPUS:85115768578
SN - 1756-8722
VL - 14
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 156
ER -